

S TALENs

(411) TCCTGCTGCTATGCCTCAT

CTTCTGGACTATCAAGGTA

Genotype

A1 (AY233288) (391) TTTTATCATATTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGAT TATCAAGGTA TGTGCCCCGTTTGCCTCTA
A2 (X70185) (391) TTTTATCATATTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGAT TATCAAGGTA TGTGCCCCGTTTGCCTCTA
A3 (AB194950) (391) TTTTATCATATTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
B1 (AB073851) (391) TTTTATCATCTTCCTCTGCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
B2 (AF121245) (391) TTTTATCATCTTCCTCTGCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
B3 (EF473977) (391) TTTTATCATCTTCCTCTGCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
B4 (AB115551) (391) TTTTATCATCTTCCTCTGCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
B5 (AB219428) (391) TTTTATCATATTCCTCTGCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
B6 (AB287316) (391) TTTTATCATCTTCCTTTGCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
C1 (DQ089760) (391) TTTTATCATCTTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
C2 (AB365451) (391) TTTTATCATATTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
C3 (X75665) (391) TTTTATCATCTTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
C4 (AB048704) (391) TTTTATCATCTTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
C5 (EU410079) (391) TTTTATCATATTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
C6 (AB493837) (391) TTTTATCATCTTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
D1 (AB246348) (391) TTTTATCATCTTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
D2 (EU594416) (391) TTTTATCATCTTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
D3 (EU594435) (391) TTTTATCATCTTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
D4 (AB033559) (391) TTTTATCATCTTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
E (AM494708) (391) TTTTATCATCTTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
F1 (AY090458) (384) TTTTATCATATTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
F2 (AY311369) (391) TTTTATCATCTTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
F3 (AB036909) (391) TTTTATCATCTTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
F4 (AF223965) (391) TTTTATCATCTTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
G (AB375168) (391) TTTTATCATATTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTG
H (AY090457) (394) TTTTATCATCTTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA
pCH 9/3091 (1673) TTTTATCATCTTCCTCTTCA TCCTGCTGCTATGCCTCAT CTTCTTATTGGTT CTTCTGGACTATCAAGGTA TGTGCCCCGTTTGCCTCTA

Surface F I I F L F I L L L C L I F L L V L L D Y Q G M L P V C P L
Polymerase F Y H L P L H P A A M P H L L V G S S G L S R Y V A R L S S

Figure S1. Comparison of HBV genotype sequences in the region targeted by the S TALEN. On the top row, the two 19 nucleotide sequences in the HBV plus strand that are targeted by each of the left and right subunits comprising the complete TALEN are highlighted in yellow. HBV genome coordinate of the first T residue of the left subunit target is underlined in parentheses. Cognates from HBV isolates, with 20 nt flanking on either side, are shown below. HBV genotypes, subgenotypes, accession numbers, pCH9/3091 and first nucleotide coordinate of each sequence are provided on the left in bold. Sequences within the S TALEN targets that are conserved in each of the genotypes are also highlighted in yellow. Adjacent amino acid sequences of Surface and Polymerase, by the pCH9/3091 plasmid, are shown on the bottom two rows. Individual amino acids are aligned to the first nucleotide of each codon.

C TALENs (2319) TATCAACACTTCCGGAGAC CGACG-----AGGCAGGTCCCCTA

Genotype

A1 (AY233288) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGACGACGAGACCGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

A2 (X70185) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGACGACGGACCGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

A3 (AB194950) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGAAACTACTGTTGTTAGACGACGGACCGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

Core/HBeAg P N A P I L S T L P E T T V L R R R D R G R S P R R R T P S P R R

Polymerase (X70185) - - M P L S Y Q H F R R L L F L D D G T E A G P L E E E L P R L A

C TALEN (2319) TATCAACACTTCCGGAGAC CGACGAGGCAGGTCCCCTA

B1 (AB073851) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGGAGACTACTGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

B2 (AF121245) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGACGAAAGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

B3 (EF473977) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGGAGACTACTGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

B4 (AB115551) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

B5 (AB219428) (2301) CACCAAATGCCCTATCTTATCCACACTTCCGGAAACTACTGTTGTTAGACGAAAGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

B6 (AB287316) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGACGACGAGTCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

C1 (DQ089760) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

C2 (AB365451) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

C3 (X75665) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGACGAAAGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

C4 (AB048704) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

C5 (EU410079) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

C6 (AB493837) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

D1 (AB246348) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGGAGACTACTGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

D2 (EU594416) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGGAGACTACTGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

D3 (EU594435) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGGAGACTACTGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

D4 (AB033559) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGGAGACTACTGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

E (AM494708) (2301) CACCAAATGCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGACGAAAGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

F1 (AY090458) (2304) CACCAAATGCCCTATCTTATCCACACTTCCGGAAACTACTGTTGTTAGACGAAAGAGGCAGGTCTCCTCGAAGAAGAACTCCCTCGCCTCGCAG

F2 (AY311369) (2301) CACCAAATGCCCTATCTTATCCACACTTCCGGAAACTACTGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

F3 (AB036909) (2301) CACCAAATGCCCTATCTTATCCACACTTCCGGAAACTACTGTTGTTAGACGAAAGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCCG

F4 (AF223965) (2301) CACCAAATGCCCTATCTTATCCACACTTCCGGAAACTACTGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

G (AB375168) (2337) CACCAAATGCCCTATCTTATCAACACTTCCGGAGACTACTGTTGTTAGACGAAAGAGGCAGGTCCCCTCGAAGAAGAACTCCCTCGCCTCGCAG

H (AY090457) (2304) CACCAAATGCCCTATCTTATCAACACTTCCGGAGACTACTGTTGTTAGACCAACGAGGCAGGTGCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

pCH 9/3091 (401) CACCAAATGCCCTATCTTATCAACACTTCCGGAGACTACTGTTCTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG

Core/HBeAg P N A P I L S T L P E T T V L R R R G R S P R R R T P S P R

Polymerase - - M P L S Y Q H F R R L L F L D D E A G P L E E E L P R L A

Figure S2. Comparison of HBV genotype sequences in the region targeted by the C TALEN. The sequences are depicted using a similar format to that described in Figure S1. HBV genotype A isolates have an additional 6 nucleotides in the in the sequence targeted by the right TALEN subunit.

P1 TALENs		(1144)	TACCCCGTTGCCCGGCAAC		CCAAGTGTGCTGACGCA																													
Genotype																																		
A1 (AY233288)	(1119)	TCTGAGTAAACAGTATATGAACCTT	TACCCCGTTGCCCGGCAAC	GGCCTGGTCTGTG	CCAAGTGTGCTGACGCA																													
A2 (X70185)	(1119)	TCTAAGTAAACAGTACATGAACCTT	TACCCCGTTGCTCGGCAAC	GGCCTGGTCTGTG	CCAAGTGTGCTGACGCA																													
A3 (AB194950)	(1119)	TCTAAGTAAACAGTATATGAACCTT	TACCCCGTTGCCCGGCAAC	GGCCTGGTCTATG	CCAAGTGTGCTGACGCA																													
B1 (AB073851)	(1119)	TCTAAGTAAACAGTATATGACCCTT	TACCCCGTTGCTCGGCAAC	GGCCTGGTCTGTG	CCAAGTGTGCTGACGCA																													
B2 (AF121245)	(1119)	TTTAAGTAAACAGTATCTGAACCTT	TACCCCGTTGCTCGGCAAC	GGCCTGGTCTGTG	CCAAGTGTGCTGACGCA																													
B3 (EF473977)	(1119)	TCTAAGCAAACAATATCTGAACCTT	TACCCCGTTGCTCGGCAAC	GGCCAGGTCTGTG	CCAAGTGTGCTGACGCA																													
B4 (AB115551)	(1119)	TTTAAGTAAACAGTATCTGAACCTT	TACCCCGTTGCTCGGCAAC	GGCCTGGTCTATG	CCAAGTGTGCTGACGCA																													
B5 (AB219428)	(1119)	TCTACACAAACAGTATTTGAACCTT	TACCCCGTTGCTCGGCAAC	GGCCAGGTCTGTG	CCAAGTGTGCTGACGCA																													
B6 (AB287316)	(1119)	TCTAAACAACAATATCTGAACCTT	TACCCCGTTA	CGGCAAC	GGCCAGGTCTGTG																													
C1 (DQ089760)	(1119)	TCTGTGTAACAATATCAGAACCTT	TACCCCGTTGCTCGGCAAC	GGTCAGGTCTTTG	CCAAGTGTGCTGACGCA																													
C2 (AB365451)	(1119)	TCTGTGTCAACAATACCTGCACCTT	TACCCCGTTGCCCGGCAAC	GGTCAGGCCTCTG	CCAAGTGTGCTGACGCA																													
C3 (X75665)	(1119)	TCTGTGTAACAATATCTGAACCTT	TACCCCGTTGCCCGGCAAC	GGTCTGGTCTTTG	CCAAGTGTGCTGACGCA																													
C4 (AB048704)	(1119)	TCTGTGTAACAATATCTGAACCTT	TACCCCGTTGCCCGGCAAC	GGCTGGTCTCTG	CCAAGTGTGCTGACGCA																													
C5 (EU410079)	(1119)	TCTGTGTAACAATATTTGACCCTT	TACCCCGTTGCTCGGCAAC	GGCCAGGTCTATG	CCAAGTGTGCTGATGCA																													
C6 (AB493837)	(1119)	TCTGTGTCAACAATATTTGCACCTT	TACCCCGTTGCCCGGCAAC	GGTCTGGTCTTTG	CCAAGTGTGCTGACGCA																													
D1 (AB246348)	(1119)	TCTGTGTAACAATACATGACCCTT	TACCCCGTTGCCCGGCAAC	GGCCAGGTCTGTG	CCAAGTGTGCTGACGCA																													
D2 (EU594416)	(1119)	TCTGTGTAACAATATCTGAACCTT	TACCCCGTTGCCCGGCAAC	GGCCAGGTCTGTG	CCAAGTGTGCTGACGCA																													
D3 (EU594435)	(1119)	TCTGTATAACAATACCTGAACCTT	TACCCCGTTGCCCGGCAAC	GGCCAGGTCTGTG	CCAAGTGTGCTGACGCA																													
D4 (AB033559)	(1119)	TCTGTGTAACAATACCTGAACCTT	TACCCCGTTGCTCGGCAAC	GGCCAGGTCTGTG	CCAAGTGTGCTGATGCA																													
E (AM494708)	(1119)	TCTGTGTAACAATACCTGAACCTT	TACCCCGTTGCCCGGCAAC	GGCCCGGTCTGTG	CCAAGTGTGCTGATGCA																													
F1 (AY090458)	(1122)	TCTATGTCAACAATACATGAACCTT	TACCCCGTTGCTCGGCAAC	GGCCAGGCCTGTG	CCAAGTGTGCTGACGCA																													
F2 (AY311369)	(1119)	TCTGTGTAACAATACATGAACCTT	TACCCCGTTGCTCGGCAAC	GGCCAGGCCTGTG	CCAAGTGTGCTGACGCA																													
F3 (AB036909)	(1119)	TCTCTGTAAACAATACATGAACCTT	TACCCCGTTGCTCGGCAAC	GGCCAGGCCTGTG	CCAAGTGTGCTGACGCA																													
F4 (AF223965)	(1119)	TCTCTGTAAACAGTACATGAACCTT	TACCCCGTTGCTCGGCAAC	GGCCAGGCCTGTG	CCAAGTGTGCTGACGCA																													
G (AB375168)	(1119)	TCTCTGTAAACAATACATGAACCTT	TACCCCGTTGCTAGGCAAC	GGCCCGGTCTGTG	CCAAGTGTGCTGACGCA																													
H (AY090457)	(1122)	TCTCTGTAAACAATACATGAACCTT	TACCCCGTTGCTCGGCAAC	GGCCAGGCCTTTG	CCAAGTGTGCTGACGCA																													
pCH 9/3091	(2401)	TCTGTGTAACAATACCTGAACCTT	TACCCCGTTGCCCGGCAAC	GGCCAGGTCTGTG	CCAAGTGTGCTGACGCA																													
Polymerase		L	C	K	Q	Y	L	N	L	Y	P	V	A	R	Q	R	P	G	L	C	Q	V	F	A	D	A	T	P	T	G	W	G	L	V

Figure S3. Comparison of HBV genotype sequences in the region targeted by the P1 TALEN. The sequences are depicted using a similar format to that described in Figure S1.

P2 TALENs		(1299)	TCGCAGCAGGTCTGGAGCA		TGATAACTCTGTTGTCCTA																											
Genotype																																
A1 (AY233288) (1274)	CGGAACTCCTAGCTGCTTGT	TTTTGC	TCGCAGC	CGGC	CTGGAGCA	AAACT	CATCGGGAC	TGATAA	TCTGT	CGTCCT	TTCTCGGAAATATA	CATC																				
A2 (X70185) (1274)	CGGAACTCCTAGCCGCTTGT	TTTTGC	TCGCAGC	CGGTCT	GGAGCA	AAAGCT	CATCGGAACT	TGACA	AAT	TCTGT	CGTCCT	CTCGCGGAAATATA	CATC																			
A3 (AB194950) (1274)	CGGAACTCCTAGCAGCTTGT	TTTTGC	TCGCAGC	CGGTCT	GGAGCA	AAACT	CATCGGGAC	TGATAA	TCTGT	CGTCCT	TTCTCGGAAATATA	CATC																				
B1 (AB073851) (1274)	CGGAACTCCTAGCCGCTTGT	TTTTGC	TCGCAGC	CAGGTCT	GGAGC	GAAACT	CATCGGGAC	TGACA	AAT	TCTGT	CGTGCT	CTCCCGCAAGTATA	CATC																			
B2 (AF121245) (1274)	CGGAACTCCTAGCCGCTTGT	TTTTGC	TCGCAGC	CAGGTCT	GGAGC	AAACT	CATCGGGAC	TGACA	AAT	TCTGT	CGTACT	CTCCCGCAAGTATA	CAGC																			
B3 (EF473977) (1274)	CGGAACTCCTAGCCGCTTGT	TTTTGC	TCGCAGC	CAGGTCT	GGAGC	AAACT	CATCGGGAC	TGACA	AAT	TCTGT	CGTCCT	TTCCCGCAAATATA	CATC																			
B4 (AB115551) (1274)	CGGAACTCCTTGCAGCTTGT	TTTTGC	TCGCAGC	CGGTCT	GGAGCA	AAACT	TATCGGGAC	TGACA	AAT	TCTGT	CGTGCTA	TCCCGCAAGTATA	CATC																			
B5 (AB219428) (1274)	CGGAACTCCTAGCTGCTTGT	TTTTGC	TCGCAGC	CAGGTCT	GGAGC	GAAACT	TATCGGGACC	GATAA	TCTGT	CGTCCT	TGTCCCGTAAATATA	CATC																				
B6 (AB287316) (1274)	CGGAACTCCTAGCCGCTTGT	TTTTGC	TCGCAGC	CAGGTCT	GGAGC	GAACT	CATCGGGAC	TGACA	AAT	TCTGT	CGTCCT	TTCCCGCAAATATA	CATC																			
C1 (DQ089760) (1274)	CGGAACTCCTAGCAGCTTGT	TTTTGC	TCGCAGC	CGGTCT	GGAGC	GAACT	TATCGGGACC	GACA	AAT	TCTGT	CGTCCT	CTCTCGGAAATACAC	CCTC																			
C2 (AB365451) (1274)	CGGAACTCCTAGCAGCTTGT	TTTTGC	TCGCAGC	CGGTCT	GGAGCA	AAACT	TATCGGGAC	TGACA	AAT	TCTGT	CGTCCT	CTCTCGGAAATACAC	CCTC																			
C3 (X75665) (1274)	CGGAACTCCTAGCGGCTTGT	TTTTGC	TCGCAGC	CGGTCT	GGAGCA	AACT	TATCGGAACT	GACA	AAT	TCTGT	CGTCCT	CTCTCGGAAATACAC	CATC																			
C4 (AB048704) (1274)	CGGAACTCCTAGCAGCTTGT	TTTCGC	TCGCAGC	CGGTCT	GGAGC	GAACAT	TCTCGGGACC	GACA	AAT	TCTGT	TCT	CTCTCGGAAATACAC	CCTC																			
C5 (EU410079) (1274)	CGGAACTCCTTGCAGCCTGT	TTTTGC	TCGCAGC	CGGTCT	GGAGCA	AACT	TATAGGAACC	GACA	AAT	TCTGT	CGTCCT	TTCTCGGAAATACAC	CCTC																			
C6 (AB493837) (1274)	CGGAACTCCTAGCAGCTTGT	TTTTGC	TCGCAGC	CGGTCT	GGAGC	GAACT	TATCGGAACT	GACA	AAT	TCTGT	CGTCCT	CTCTCGGAAATACAC	CCTC																			
D1 (AB246348) (1274)	CGGAACTCCTAGCCGCTTGT	TTTTGC	TCGCAGC	CAGGTCT	GGAGCA	AACT	TCTCGGGACC	GATAA	CTGT	TCT	CTCCCGCAAATATA	CATC																				
D2 (EU594416) (1274)	CGGAACTCCTAGCCGCTTGT	TTTTCGC	TCGCAGC	CAGGTCT	GGAGCA	AACT	TCTCGGGACC	GATAA	CTGT	TCT	CTCCCGCAAATATA	CATC																				
D3 (EU594435) (1274)	CGGAACTCCTAGCCGCTTGT	TTTTGC	TCGCAGC	CAGGTCT	GGAGCA	AACT	TCTCGGGACC	TGATAA	CTGT	CGTCCT	CTCCCGCAAATATA	CATC																				
D4 (AB033559) (1274)	CGGAACTCCTAGCCGCTTGT	TTTTGC	TCGCAGC	CAGGTCT	GGAGCA	AACT	TCTCGGAACT	TGACA	AAT	TCTGT	CGTCCT	CTCCCGCAAATATA	CATC																			
E (AM494708) (1274)	CGGAACTCCTAGCCGCTTGT	TTTTGC	TCGCAGC	CAGGTCT	GGAGC	GAACT	TATCGGGACC	GATAA	TCTGT	CGTCT	CTCCCGCAAATATA	CATC																				
F1 (AY090458) (1277)	CAGAACTCCTTGCAGCTTGT	TTTCGC	TCGCAGC	CGGTCT	GGAGC	GAACT	CATCGGGACC	GACA	AAT	TCTGT	CGTCCT	CTCTAGGAAGTACAC	CCTC																			
F2 (AY311369) (1274)	CGGAACTCCTAGCAGCTTGT	TTTCGC	TCGCAGC	CGGTCT	GGAGC	GACTCT	TAATGGCACC	GACA	AAT	TCTGT	CGTCCTA	TCTAGGAAGTACAC	CCTC																			
F3 (AB036909) (1274)	CGGAACTCCTTGCAGCCTGT	TTTCGC	TCGCAGC	CGGTCT	GGAGC	GAACAT	TATCGGGACC	GACA	AAT	TCTGT	CGTCCT	CTCTAGGAAGTACAC	CCTC																			
F4 (AF223965) (1274)	CGGAACTCCTTGCAGCTTGT	TTTCGC	TCGCAGC	CGGTCT	GGAGC	GAATAT	CATCGGGACC	GACA	AAT	TCTGT	CGTACT	CTCTAGGAAGTACAC	CCTC																			
G (AB375168) (1274)	CGGAACTCCTAGCTGCTTGT	TTTTGC	TCGCAGC	CGGTCT	GGAGCA	AAACT	CATTTGGGAC	TGACA	AAT	TCTGT	CGTCCT	TTCTCGGAAATATA	CATC																			
H (AY090457) (1277)	CGGAACTCCTAGCAGCTTGT	TTTCGC	TCGCAGC	CGGTCT	GGAGC	GGACAT	TATCGGGACC	TGACA	AAT	CGTTGTCCT	GTCTCGGAAAGTACAC	CCTC																				
pCH 9/3091 (2556)	CGGAACTCCTAGCCGCTTGT	TTTTGC	TCGCAGC	CAGGTCT	GGAGCA	AACT	TATCGGGACC	TGATAA	CTGT	CGTCCTA	TCCCGCAAATATA	CATC																				
Polymerase			E	L	L	A	A	C	F	A	R	S	R	S	G	A	N	I	I	G	T	D	N	S	V	V	L	S	R	K	Y	T

Figure S4. Comparison of HBV genotype sequences in the region targeted by the P2 TALEN. The sequences are depicted using a similar format to that described in Figure S1.




Figure S5. Survival assay after co-transfection with GFP- and TALEN-expressing plasmids.

A. Following transfection of Huh7 cells with plasmids encoding TALENs and GFP in the presence or absence of HBV target DNA, GFP-positive cells were counted in three representative low power fields (LPF, 100 ×) of experiments performed in triplicate. Mean numbers of fluorescent cells observed are shown with standard errors of the mean indicated by error bars. **B.** Representative low power fields of cells transfected with each of the plasmid combinations.




Figure S6. HBsAg concentrations in culture supernatants of HepG2.2.15 cells that were subjected to repeat transfections with plasmids encoding each of the panel of 4 HBV-targeting TALENs under hypothermic (30°C) temperatures. Data are represented as the means and the error bars indicate the standard errors of the mean. Statistically significant differences between values obtained after transfection of cells with each of the TALENs and values without TALEN transfection (No TALEN) are indicated by asterisks (*: $p < 0.05$).




Figure S8. Equivalent reporter gene expression in groups of mice that were subjected to HDI.

A. Each animal from the three groups of mice was subjected to bioluminescence imaging following injection of the TALENs, HBV sequences and a Firefly luciferase-encoding plasmid. **B.** Mean relative light units emitted from the hepatic region was determined for each of the groups of animals. Values are presented as the means with error bars indicating standard deviations.




Figure S9. Representative liver histology (hematoxylin and eosin staining) obtained from liver sections of each animal that had been subjected to HDI with or without TALEN-expressing plasmids. Low power fields (100 ×) are shown.

Table S1. BLAST analysis of the *Mus musculus* genome to identify potential binding sites of combined and individual left and right subunits (SL and SR) of the S TALEN.

Potential combined SL and SR sites	Chrom. No.	Nucleotide Range	S TALEN Sites		Identities [#]	Sequence ID
			SL	SR		
			<i>TCCTGCTGCTATGCCTCAT</i> AGGACGACGATACGGAGTA	<i>CTTCTGGACTATCAAGGTA</i> GAAGACCTGATAGTTCCAT		
	6	6830661 to 6830677 11962065 to 11962080 41232469 to 41232483	●CCTGCTGCTATGCCTCA●* TCCTGCTGCTATGCCT●●●	CTTCTGGACTATCAA●●●●	17/19 16/19 15/19	NW_001030820.1
	4	44188029 to 44188045 31532806 to 31532820 8318087 to 8318104 36732721 to 36732735	●●CTGCTGCTATGCCTCAT ●CCTGCTGCTATGCCT●●● ●CCTGCTGCTA●GCCTCAT	●TTCTGGACTATCAAG●●●	17/19 15/19 15/19 17/19	NT_187032.1
	4	22544951 to 22544966 10954765 to 10954779	TCCTGCTGCTATGCCT●●●	●●●●TGGACTATCAAGGTA	16/19 15/19	NT_187033.1
	8	9218161 to 9218176 26838227 to 26838244	TCCTGCTGCTATGCCT●●●	●TTCTGGA●TATCAAGGTA	16/19 17/19	NT_078575.7
	9	3697632 to 3697647 44495841 to 44495855	TCCTGCTGCTATGCCT●●●	CTTCTGGACTATCAA●●●●	16/19 15/19	NT_039474.8
	13	1175041 to 1175059 4966540 to 4966554	TCCTGCTGCT●TGCCTCAT	●●●●TGGACTATCAAGGTA	18/19 15/19	NW_001030529.1
	9	43318590 to 43318605 44102972 to 44102987 10709989 to 10710005	TCCTGCTGCTATGCCT●●● TCCTGCTGCTATGCCT●●●	CTTCTGGACTA●CAAGG●●	16/19 16/19 16/19	NW_001030907.1
	7	1111381 to 1111396 38299233 to 38299248 53113291 to 53113306 50396556 to 50396574 2339469 to 2339486 8016639 to 8016656 2033241 to 2033255	TCCTGCTGCTATGCCT●●● TCCTGCTGCTATGCCT●●● TCCTGCTGCTATGCCT●●● TCCTGCTGCT●TGCCTCAT TCCTGCTGCTATG●CTCA● TCCTGCTGCT●TGCCTCA●	CTTCTGGACTATCAA●●●●	16/19 16/19 16/19 18/19 17/19 17/19 15/19	NT_039433.8
	3	41300341 to 41300356 27971181 to 27971195 66053798 to 66053816	TCCTGCTGCTATGCCT●●●	●TTCTGGACTATCAAG●●● CTTCTGG●CTATCAAGGTA	16/19 15/19 18/19	NT_039240.8
	17	69593674 to 69593692 30114485 to 30114500	TCCTGCT●CTATGCCTCAT	●●TCTGGACTATCAAGGT●	18/19 16/19	NT_039649.8

Potential individual SL sites	13	17430998 to 17431014 2227826 to 2227841	TCCTGCTGCTATGCCT●● TCCTGCTGCTATGCCT●●●		17/19 16/19	NW_001030517.1
	6	845523 to 845539 5969096 to 5969111	●CCTGCTGCTATGCCTCA● TCCTGCTGCTATGCCT●●●		17/19 16/19	NT_039360.8
	4	12854748 to 12854763 25385538 to 25385553	TCCTGCTGCTATGCCT●●● TCCTGCTGCTATGCCT●●●		16/19 16/19	NT_039264.7
	9	36145333 to 36145348 36938186 to 36938201	TCCTGCTGCTATGCCT●●● TCCTGCTGCTATGCCT●●●		16/19 16/19	NT_039472.8
	14	28926064 to 28926081 60263242 to 60263256	●CCTGCTGCTATGCCTCAT ●CCTGCTGCTATGCCT●●●		18/19 15/19	NT_039606.8
	19	49262317 to 49262333 2286312 to 2286326 15839462 to 15839476	TCCTGCTGCTATGCCTC●● ●●CTGCTGCTATGCCTC●● TCCTGCTGCTATGCC●●●●		17/19 15/19 15/19	NT_039687.8
	7	22820518 to 22820533 37540231 to 37540246 34806807 to 34806825	TCCTGCTGCTATGCCT●●● TCCTGCTGCTATGCCT●●● TCCTGCTGCT●TGCCTCAT		16/19 16/19 18/19	NW_001030877.1
	11	55118539 to 55118554 60207885 to 60207900	TCCTGCTGCTATGCCT●●● TCCTGCTGCTATGCCT●●●		16/19 16/19	NT_096135.6
Potential individual SR sites	3	27971181 to 27971195 66053798 to 66053816		●TTCTGGACTATCAAG●●● CTTCTGG●CTATCAAGGTA	15/19 18/19	NT_039240.8
	11	8445188 to 8445204 12712726 to 12712742		CTTCTGG●CTATCAAGG●● ●TTCTG●ACTATCAAGGT●	16/19 16/19	NW_001030434.1
	2	16581880 to 16581894 25991220 to 25991236 68974756 to 68974772		CTTCTGGACTATCAA●●●● ●TTCTG●ACTATCAAGGT● CTTCTGGACT●TCAAGG●●	15/19 16/19 16/19	NT_039207.8
	16	61477073 to 61477087 36662006 to 36662022 71304901 to 71304917		●TTCTGGACTATCAAG●●● CTTCTGGACTA●CAAGG●● ●TTCTGGA●TATCAAGGT●	15/19 16/19 16/19	NW_001030584.1
	19	26586727 to 26586741 26777773 to 26777787 26955911 to 26955925		CTTCTGGACTATCAA●●●● CTTCTGGACTATCAA●●●● CTTCTGGACTATCAA●●●●	15/19 15/19 15/19	NT_039687.8

#A minimum sequence identity between TALEN subunit cognates and sites within the *Mus musculus* genome of 15 out of 19 sense or antisense nucleotides was used as a cut off.

*Mismatches between the TALEN subunit cognates and the aligned sequence in the *Mus musculus* genome are indicated by ‘●’.

Table S2. BLAST analysis of the human genome to identify potential binding sites of combined and individual left and right subunits (SL and SR) of the S TALEN.

Potential combined SL and SR sites	Chrom. No.	Nucleotide Range	S TALEN Sites		Identities	Sequence ID
			SL	SR		
			<i>TCCTGCTGCTATGCCTCAT</i> AGGACGACGATACGGAGTA	<i>CTTCTGGACTATCAAGGTA</i> GAAGACCTGATAGTTCCAT		
	5	5316824 to 5316838 1348622 to 1348638	●●CTGCTGCTATGCCTC●●	●TTCTGGACTATC●AGGT●	15/19 16/19	NW_004078023.1
	6	16508260 to 16508274 36973928 to 36973944 28906310 to 28906326 66068358 to 66068374	●●CTGCTGCTATGCCTC●● ●●CTGCTGCTAT●CCTCAT	●TTCTGGACTAT●AAGGT● ●TTCTGGACTATC●AGGT●	15/19 16/19 16/19 16/19	NW_004078028.1
	3	52993974 to 52993988 81226837 to 81226851 9589025 to 9589042	TCCTGCTGCTATGCC●●●● ●●●TGCTGCTATGCCTCA●	●TTCTGGA●TATCAAGGTA	15/19 15/19 17/19	NT_005612.16
	17	28496793 to 28496807 35558057 to 35558074 13845926 to 13845940	●●●●GCTGCTATGCCTCAT ●CCTGCTGCT●TGCTCAT	●●●●TGGACTATCAAGGTA	15/19 17/19 15/19	NT_010783.15
	16	9515596 to 9515610 10180724 to 10180741 20197304 to 20197318	●●●TGCTGCTATGCCTCA●	CTTCTGGACTATCAAGGT● ●●●●TGGACTATCAAGGTA	15/19 18/19 15/19	NT_010393.16
	4	28481514 to 28481528 86675613 to 86675630 5401736 to 5401752 26630796 to 26630810 91203543 to 91203560 42836405 to 42836421	TCCTGCTGCTATGCC●●●● ●CCTGCTGCT●TGCTCAT TCCTGCTGC●ATGCCTC●●	●●●●TGGACTATCAAGGTA ●TTCTGGACTAT●AAGGTA CTTCTG●ACTATCAAGG●●	15/19 17/19 16/17 15/19 17/19 16/19	NT_016354.19
	19	8260049 to 8260063 5398156 to 5398173	TCCTGCTGCTATGCC●●●●	CTTCT●GACTATCAAGGT●	15/19 17/19	NT_011109.16
	9	32244124 to 32244141 26866298 to 26866315	●CCTGCTGCTA●GCCTCAT	CTTCTGGA●TATCAAGGT●	17/19 17/19	NT_008413.18
	1	61198693 to 61198710 11611961 to 11611975 47930542 to 47930556 66083096 to 66083110	TCCTGCTGCT●TGCTCA●	●●TCTGGACTATCAAGG●● ●●●CTGGACTATCAAGGT● ●●●CTGGACTATCAAGGT●	17/19 15/19 15/19 15/19	NT_032977.9

	6	10893712 to 10893726 9894805 to 9894819 14658716 to 14658733	●CCTGCTGCTATGCCT●●●	●TTCTGGACTATCAAG●●● ●TTCTGGACT●TCAAGGTA	15/19 15/19 17/19	NT_007299.13
Potential individual SL sites	22	13395721 to 13395736 23229742 to 23229758 26356393 to 26356409 30107958 to 30107974	●CCTGCTGCTATGCCTC●● TCCTGCTGCTAT●CCTC●● TCCTGCTGCT●TGCCTC●● ●CCTGCTGCT●TGCCTCA		16/19 16/19 16/19 16/19	NW_004078112.1
	15	69598949 to 69598963 7011373 to 7011389 42322452 to 42322468	●CCTGCTGCTATGCCT●●● ●●CTGCTGCT●TGCCTCAT ●●CTGCTGCTAT●CCTCAT●		15/19 16/19 16/19	NW_004078084.1
	17	12292150 to 12292164 5230569 to 5230586	●●●●GCTGCTATGCCTCAT ●CCTGCTGCT●TGCCTCAT		15/19 17/19	NW_001838454.2
	3	11943588 to 11943602 20444778 to 20444795 1113755 to 1113771	●CCTGCTGCTATGCCT●●● TCCTGCTGCTAT●CCTCA● ●●CTGCTGCTATGC●TCAT		15/19 17/19 16/19	NW_001838877.2
	11	3402649 to 3402663 21709223 to 21709239	●●CTGCTGCTATGCCTC●● TCCTGCTGCT●TGCCTC●●		15/19 16/19	NT_033899.8
	6	16509724 to 16509738 36971717 to 36971733	●●CTGCTGCTATGCCTC●● ●●CTGCTGCTAT●CCTCAT		15/19 16/19	NT_025741.15
Potential individual SR sites	13	67246550 to 67246566 36698126 to 36698140 37005816 to 37005830 32823986 to 32824003		CCTTCTGGACTATCAAGG●● CCTTCTGGACTATCAA●●●● ●●●CTGGACTATCAAGGT● ●TTCTGGA●TATCAAGGTA	17/19 15/19 15/19 17/19	NT_024524.14
	21	8582147 to 8582162 26035956 to 26035973		●●●CTGGACTATCAAGGTA CCTTCTGGACTATC●AGGT●	16/19 17/19	NT_011512.11
	12	2866821 to 2866835 485378 to 485394		●●●CTGGACTATCAAGGT● ●●TTCTGGACTATCCAGGT●	15/19 16/19	NW_001838060.2
	1	5704171 to 5704185 23791575 to 23791591		●●●CTGGACTATCAAGGT● CCTTCTGGACTA●CAAGG●●	15/19 16/19	NW_001838579.2
	9	49639304 to 49639318 30386318 to 30386335		●TTCTGGACTATCAAG●●● ●TTCTGGACTA●CAAGGTA	15/19 17/19	NT_008470.19

#A minimum sequence identity between TALEN subunit cognates and sites within the human genome of 15 out of 19 sense or antisense nucleotides was used as a cut off.

*Mismatches between the TALEN subunit cognates and the aligned sequence in the human genome are indicated by ‘●’.

Table S3. BLAST analysis of the *Mus musculus* genome to identify potential binding sites of combined and individual left and right subunits (CL and CR) of the C TALEN.

Potential combined CL and CR sites	Chrom. No.	Nucleotide Range	C TALEN Sites		Identities	Sequence ID
			CL	CR		
			<i>TATCAACTTCCGGAGAC</i> ATAGTTGTGAAGGCCTCTG	<i>CGACGAGGCAGGTCCCCTA</i> GCTGCTCCGTCCAGGGGAT		
Potential combined CL and CR sites	5	18010816 to 18010830 19827052 to 19827066 16218494 to 16218508	●●TCAAACTTCCGGAG●● ●●TCAAACTTCCGGAG●●	●●●●GAGGCAGGTCCCCTA	15/19 15/19 15/19	NW_001030796.1
	9	47261339 to 47261354 7863713 to 7863727	TATCAA●ACTTCCGGA●●●	●●●●GAGGCAGGTCCCCTA	15/19 15/19	NT_039474.8
	17	38384398 to 38384414 43566525 to 43566540 70416673 to 70416687	●ATCAAACTTCC●GAGA● ●●●CAAACTTCC●AGAC	●●●●GAGGCAGGTCCCCTA	16/19 15/19	NT_039649.8
			15/19			
Potential CL sites	3	38866300 to 38866314 53841380 to 53841397 34012433 to 34012449 59437720 to 59437735	●ATCAAACTTCCGGA●●● TATCA●CACTTCCGGAGA● ●●TCAA●ACTTCCGGAGAC TATCA●CACTTCCGGA●●●		15/19 17/19 16/19 15/19	NT_039240.8
	5	531836 to 531850 2348932 to 2348946	●●TCAAACTTCCGGAG●● ●●TCAAACTTCCGGAG●●		15/19 15/19	NT_078458.7
	14	6519500 to 6519514 6659119 to 6659133 6798768 to 6798782 26304835 to 26304850	●ATCAAACTTCCGGA●●● ●ATCAAACTTCCGGA●●● ●ATCAAACTTCCGGA●●● ●●●CAAACTTCC●GGAGAC		15/19 15/19 15/19 15/19	NT_039606.8
			16/19			
2	93924002 to 93924019 9619835 to 9619851 87013076 to 87013092	●ATCAAACTTCC●GAGAC TATCAAACTTCC●GGAG●● ●●TCAACAC●TCCGGAGAC		17/19 16/19 16/19	NT_039207.8	
Potential CR sites	Sequences in the <i>Mus musculus</i> genome with 15 or more nucleotide identities to the CR cognate were not found.					

#A minimum sequence identity between TALEN subunit cognates and sites within the *Mus musculus* genome of 15 out of 19 sense or antisense nucleotides was used as a cut off.

*Mismatches between the TALEN subunit cognates and the aligned sequence in the *Mus musculus* genome are indicated by ‘●’.

Table S4. BLAST analysis of the human genome to identify potential binding sites of combined and individual left and right subunits (CL and CR) of the C TALEN.

Potential combined CL and CR sites	Chrom. No.	Nucleotide Range	C TALEN Sites		Identities	Sequence ID
			CL	CR		
				<i>TATCAACTTCCGGAGAC</i> ATAGTTGTGAAGGCCTCTG	<i>CGACGAGGCAGGTCCCCTA</i> GCTGCTCCGTCCAGGGGAT	
	3	51696616 to 51696632 65720310 to 65720324	TATCAACTTC●GGAG●●	●●●●GAGGCAGGTCCCCTA	16/17 15/19	NT_022517.18
	2	56850349 to 56850365 15604047 to 15604063	●●TCAACTTC●GGAGAC	●GACGAGGCAGG●CCCCT●	16/19 16/19	NW_004078008.1
	21	4560786 to 4560802 30289322 to 30289338	●●TCAACTTC●GGAGAC	CGAC●AGGCAGGTCCCC●●	16/19 16/19	NW_004078109.1
Potential CL sites	8	4869274 to 4869289 12795942 to 12795958	●●●CAACTTCCGGAGAC ●●TCAACTTC●GGAGAC		16/19 16/19	NT_167187.1
	7	30035998 to 30036012 36477879 to 36477895 42858728 to 42858744	●●TCAACTTCCGGAG●● TATCAACTTC●GGAG●● ●●TCAACTTC●GGAGAC		15/19 16/19 16/19	NT_007819.17
	6	5016435 to 5016449 31733101 to 31733119	●●TCAACTTCCGGAG●● TATCAACTTCC●GAGAC		15/19 18/19	NT_007592.15
	3	30147609 to 30147625 55554086 to 55554102	TATCAACA●TTCCGGAG●● ●●TCAACTTC●GGAGAC		16/19 16/19	NT_005612.16
Potential CR sites	2	553285 to 553301 830629 to 830645		●GACGAGGCAGG●CCCCT● ●GACGAGGCAGG●CCCCT●	16/17 16/17	NT_022135.16

#A minimum sequence identity between TALEN subunit cognates and sites within the human genome of 15 out of 19 sense or antisense nucleotides was used as a cut off.

*Mismatches between the TALEN subunit cognates and the aligned sequence in the human genome are indicated by ‘●’.